Heart and Circulation
-
Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene
This plain language summary from Future Cardiology describes the results of a study looking at the effects of a medicine called ARRY-371797 (also known as PF-07265803) in people with dilated cardiomyopathy caused by a faulty LMNA gene.
-
Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.
-
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary
A new plain language summary of the ATTR-ACT study looks at the participants who took placebo to learn how transthyretin amyloid cardiomyopathy progressed without treatment.
-
Is the sodium in sodium oxybate a risk for heart health? A plain language summary of publication
This plain language summary has been published to help people with narcolepsy who take the treatment sodium oxybate understand if there are any risks to their cardiovascular health.
-
Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary
The new plain language summary helps people with transthyretin amyloid cardiomyopathy understand the disease, its treatment, and results from the ATTR-ACT study.
-
A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy
Written by Cynthia Burstein Waldman (a patient author) and Anjali Owens, this new article called ‘A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy’ has been published in Future Cardiology.